Drugdocs | Tymlos

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Tymlos

Chemical Name	abaloparatide
Dosage Form	Injection (subcutaneous; 3120 mcg/1.56 mL)
Drug Class	Hormones
System	Musculoskeletal
Company	Radius Health Inc
Approval Year	2017

Indication

To treat osteoporosis in postmenopausal women at high risk of fracture.

Last updated on 6/11/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Tymlos (abaloparatide) Prescribing Information	2018	Radius Health, Inc., Waltham, MA

Document Title	Year	Source
Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.	2019	Maturitas

Document Title	Year	Source
American Association Of Clinical Endocrinologists/American College Of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2020 update.	2020	Endocrine
Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society* clinical practice guideline.	2019	The Journal of Clinical Endocrinology